458 related articles for article (PubMed ID: 32534590)
1. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
[TBL] [Abstract][Full Text] [Related]
2. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
3. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
5. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.
Smidt LCA; Visseren FLJ; de Ranitz-Greven WL; Nathoe HM; Kappelle LJ; de Borst GJ; de Valk HW; Westerink J;
Cardiovasc Diabetol; 2021 Sep; 20(1):181. PubMed ID: 34496847
[TBL] [Abstract][Full Text] [Related]
6. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
8. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
Wittbrodt E; Chamberlain D; Arnold SV; Tang F; Kosiborod M
Diabetes Obes Metab; 2019 Aug; 21(8):1985-1989. PubMed ID: 30968543
[TBL] [Abstract][Full Text] [Related]
9. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
10. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
[TBL] [Abstract][Full Text] [Related]
11. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
[TBL] [Abstract][Full Text] [Related]
12. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care.
Hinton W; Feher M; Munro N; Joy M; de Lusignan S
Diabet Med; 2020 Sep; 37(9):1499-1508. PubMed ID: 32128875
[TBL] [Abstract][Full Text] [Related]
14. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
[TBL] [Abstract][Full Text] [Related]
15. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
Wong ND; Fan W; Pak J
Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
[TBL] [Abstract][Full Text] [Related]
16. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
17. Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i.
Lamacchia O; Sorrentino MR
Curr Vasc Pharmacol; 2021; 19(2):233-240. PubMed ID: 32183678
[TBL] [Abstract][Full Text] [Related]
18. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Carbone S; Dixon DL
Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
[TBL] [Abstract][Full Text] [Related]
19. Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
Shao H; Shi L; Fonseca VA
Diabetes Care; 2020 Jul; 43(7):1530-1536. PubMed ID: 32345650
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
Xiang B; Zhao X; Zhou X
Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]